Cardiac safety of afatinib: a review of data from clinical trials

BACKGROUND: Afatinib is an oral irreversible ErbB family blocker that targets epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and HER4 (ErbB4) and is approved for the first-line treatment of advanced non–small cell lung cancer (NSCLC) with certai...

Descripción completa

Detalles Bibliográficos
Autores principales: Ewer, Michael S., Patel, Kalpesh, O’Brien, Dennis, Lorence, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837143/
https://www.ncbi.nlm.nih.gov/pubmed/33530147
http://dx.doi.org/10.1186/s40959-015-0006-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837143/
https://www.ncbi.nlm.nih.gov/pubmed/33530147
http://dx.doi.org/10.1186/s40959-015-0006-7

Ejemplares similares